目的 探討貝伐單抗聯(lián)合紫杉醇和奈達(dá)鉑治療晚期及復(fù)發(fā)宮頸癌的臨床療效。方法 選取2013年2月—2015年2月遼寧省腫瘤醫(yī)院婦科收治的晚期及復(fù)發(fā)宮頸癌患者88例,按照治療方法不同分為對(duì)照組和治療組,每組各44例。對(duì)照組第1天給予紫杉醇注射液175 mg/m²,加入500 mL生理鹽水中靜脈滴注,3 h內(nèi)滴完。第2天給予注射用奈達(dá)鉑80 mg/m²進(jìn)行靜脈滴注。治療組在給予對(duì)照組藥物化療前給予貝伐單抗注射液7.5 mg/kg,加入500 mL生理鹽水中靜脈滴注,首次應(yīng)用貝伐單抗注射液輸注時(shí)間應(yīng)持續(xù)90 min,以后可縮短至60 min,其他治療同對(duì)照組。兩組均以3周為1個(gè)療程,連續(xù)治療3個(gè)療程。觀察兩組的臨床療效和生活質(zhì)量改善情況,觀察兩組患者不良反應(yīng)發(fā)生情況。結(jié)果 治療后,對(duì)照組有效率為31.82%,臨床獲益率為70.45%;治療組有效率為56.82%,臨床獲益率為88.64%,兩組有效率、臨床獲益率比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。對(duì)照組和治療組生存質(zhì)量改善率分別為65.91%、84.09%,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。兩組不良反應(yīng)發(fā)生情況比較差異無統(tǒng)計(jì)學(xué)意義。結(jié)論 貝伐單抗聯(lián)合紫杉醇和奈達(dá)鉑治療晚期及復(fù)發(fā)宮頸癌具有較好的臨床療效,可顯著提高患者的生存質(zhì)量,不良反應(yīng)并未增加,具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of bevacizumab combined with paclitaxel and nedaplatin in treatment of advanced and recurrent cervical cancer. Methods Patients (88 cases) with advanced and recurrent cervical cancer in Department of Gynaecology of Liaoning Cancer Hospital from February 2013 to February 2015 were enrolled in this study. According to the different treatment plan, patients were divided into treatment (44 cases) and control (44 cases) groups. The patients in the control group were iv administered with Paclitaxel Injection on the first day, 175 mg/m² added into normal saline 500 mL, and dropped down in 3 h. And they were iv administered with Nedaplatin for injection 80 mg/m². The patients in the treatment group were iv administered with Bevacizumab Injection before giving the chemotherapy drugs of control group, 7.5 mg/kg added into normal saline 500 mL, for the first time the infusion time should be continued for 90 min, later reduced to 60 min, and other treatment was the same as the control group. One course of treatment included 3 weeks, and two groups were treated for three courses. The clinical efficacy and improvement of life quality in two groups were evaluated, and the adverse reactions in two groups were observed. Results After treatment, the total effective rate of control group was 31.82%, and the clinical benefit rate was 70.45%, while the total effective rate of treatment group was 56.82%, and the clinical benefit rate was 88.64%, and there were differences between two groups (P< 0.05). The improvement rate of life quality in the control and treatment groups were 65.91% and 84.09%, respectively, and there were differences between two groups (P< 0.05). There was no difference between two groups about the situation of adverse reactions. Conclusion Bevacizumab combined with paclitaxel and nedaplatin has the good clinical effect in treatment of advanced and recurrent cervical cancer, and can significantly improve the life quality in patients, and at the same time adverse reactions do not increase, which has a certain clinical application value.